Oncology Burst
FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
For patients with KRASG12C-mutated NSCLC who are treated with sotorasib, there is a lack of biomarkers to guide treatment decisions. We therefore investigated the clinical…
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic nonāsmall-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1)…
ESMO is Europeās leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic nonāsmall-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1)…
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors.…
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors.…
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors.…
DATE: Friday 12th / Saturday 13th April 2024 VENUE: Johnstown House Hotel, Enfield, Co Meath
The detection of tumor DNA in the supernatant of guide sheath flush fluid collected during r-EBUS bronchoscopy represents a sensitive and complementary method for genotyping…
Uncommon EGFR mutations represent a rare subgroup of non-small cell lung cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in…